JPWO2019122065A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019122065A5 JPWO2019122065A5 JP2020534447A JP2020534447A JPWO2019122065A5 JP WO2019122065 A5 JPWO2019122065 A5 JP WO2019122065A5 JP 2020534447 A JP2020534447 A JP 2020534447A JP 2020534447 A JP2020534447 A JP 2020534447A JP WO2019122065 A5 JPWO2019122065 A5 JP WO2019122065A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen atom
- pyrrolo
- pyrimidin
- dihydro
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1771402 | 2017-12-21 | ||
| FR1771402A FR3075795A1 (fr) | 2017-12-21 | 2017-12-21 | Nouveaux composes inhibiteurs de mtor |
| PCT/EP2018/086074 WO2019122065A1 (fr) | 2017-12-21 | 2018-12-20 | Composes inhibiteurs de mtor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021506917A JP2021506917A (ja) | 2021-02-22 |
| JPWO2019122065A5 true JPWO2019122065A5 (ko) | 2023-06-13 |
Family
ID=62017455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020534447A Ceased JP2021506917A (ja) | 2017-12-21 | 2018-12-20 | ｍＴＯＲ阻害剤化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11518767B2 (ko) |
| EP (1) | EP3727390B1 (ko) |
| JP (1) | JP2021506917A (ko) |
| KR (1) | KR20200103032A (ko) |
| CN (1) | CN111918654A (ko) |
| AU (1) | AU2018392761B2 (ko) |
| BR (1) | BR112020012201A2 (ko) |
| CA (1) | CA3086243A1 (ko) |
| CL (1) | CL2020001686A1 (ko) |
| FR (1) | FR3075795A1 (ko) |
| IL (1) | IL275531B2 (ko) |
| MX (1) | MX2020006436A (ko) |
| RU (1) | RU2020123899A (ko) |
| SA (1) | SA520412289B1 (ko) |
| SG (1) | SG11202005868XA (ko) |
| WO (1) | WO2019122065A1 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110407703A (zh) * | 2019-08-02 | 2019-11-05 | 深圳振强生物技术有限公司 | 吲哚布芬杂质的制备方法 |
| EP4370517A1 (en) | 2021-07-12 | 2024-05-22 | Galderma Holding SA | Synthesis of chiral substituted pyrazolopyrimidine compounds |
| EP4396188A1 (en) | 2021-08-31 | 2024-07-10 | Galderma Holding SA | Novel mtor inhibitor compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005028434A2 (en) | 2003-09-18 | 2005-03-31 | Conforma Therapeutics Corporation | Novel heterocyclic compounds as hsp90-inhibitors |
| EP1951724B1 (en) * | 2005-11-17 | 2011-04-27 | OSI Pharmaceuticals, Inc. | FUSED BICYCLIC mTOR INHIBITORS |
| AU2008323694A1 (en) | 2007-11-07 | 2009-05-14 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| EP2276763A1 (en) | 2008-03-19 | 2011-01-26 | OSI Pharmaceuticals, Inc. | Mtor inhibitor salt forms |
| US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
| JP6047149B2 (ja) * | 2011-05-04 | 2016-12-21 | インテリカイン， エルエルシー | 併用の医薬組成物およびその使用 |
| EP2704723A4 (en) * | 2011-05-06 | 2014-12-24 | Univ California | TREATMENT OF POLYCYSTIC DISEASES |
| WO2013050508A1 (en) * | 2011-10-07 | 2013-04-11 | Cellzome Limited | Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mtor inhibitors |
| US9174994B2 (en) | 2011-11-23 | 2015-11-03 | Intellikine, Llc | Enhanced treatment regimens using mTor inhibitors |
| CA2833701A1 (en) * | 2013-11-19 | 2015-05-19 | Pharmascience Inc. | Protein kinase inhibitors |
| WO2017186760A1 (en) * | 2016-04-29 | 2017-11-02 | Merck Patent Gmbh | Materials for organic electroluminescent devices |
| FR3075794A1 (fr) | 2017-12-21 | 2019-06-28 | Galderma Research & Development | Nouveaux composes inhibiteurs de mtor |
-
2017
- 2017-12-21 FR FR1771402A patent/FR3075795A1/fr active Pending
-
2018
- 2018-12-20 JP JP2020534447A patent/JP2021506917A/ja not_active Ceased
- 2018-12-20 KR KR1020207020410A patent/KR20200103032A/ko not_active Application Discontinuation
- 2018-12-20 BR BR112020012201-7A patent/BR112020012201A2/pt unknown
- 2018-12-20 SG SG11202005868XA patent/SG11202005868XA/en unknown
- 2018-12-20 RU RU2020123899A patent/RU2020123899A/ru unknown
- 2018-12-20 CA CA3086243A patent/CA3086243A1/en active Pending
- 2018-12-20 AU AU2018392761A patent/AU2018392761B2/en not_active Expired - Fee Related
- 2018-12-20 IL IL275531A patent/IL275531B2/en unknown
- 2018-12-20 EP EP18826025.1A patent/EP3727390B1/fr active Active
- 2018-12-20 CN CN201880090046.3A patent/CN111918654A/zh active Pending
- 2018-12-20 MX MX2020006436A patent/MX2020006436A/es unknown
- 2018-12-20 WO PCT/EP2018/086074 patent/WO2019122065A1/fr unknown
-
2020
- 2020-06-19 US US16/907,122 patent/US11518767B2/en active Active
- 2020-06-19 CL CL2020001686A patent/CL2020001686A1/es unknown
- 2020-06-21 SA SA520412289A patent/SA520412289B1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5911854B2 (ja) | 有機化合物 | |
| EP3781571B1 (en) | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) | |
| ES2929528T3 (es) | Derivados de pirazolopirimidina como inhibidores de BTK para el tratamiento del cáncer | |
| AU2011258465B2 (en) | Bicyclic heteroaryl kinase inhibitors and methods of use | |
| AU2009324894B2 (en) | MLK inhibitors and methods of use | |
| JP2021532101A (ja) | インターロイキン−１活性の阻害剤としてのスルホンイミドアミド化合物 | |
| KR20160145796A (ko) | BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온 | |
| CA2774731C (en) | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | |
| CN111867590B (zh) | Atr激酶的杂环抑制剂 | |
| EP3555093A1 (en) | Inhibitors of rip1 kinase and methods of use thereof | |
| EP3976189B1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| AU2016243939A1 (en) | Heterocyclic compounds as LSD1 inhibitors | |
| AU2009322900A1 (en) | Organic compounds | |
| UA119848C2 (uk) | Трициклічні гетероцикли як інгібітори білків бет | |
| JP2009507032A (ja) | 新規なイミダゾ系複素環 | |
| SG185644A1 (en) | Macrocyclic compounds as trk kinase inhibitors | |
| SG187548A1 (en) | New aminopyrazoloquinazolines | |
| TWI811400B (zh) | 經進一步取代之三唑并喹噁啉衍生物 | |
| WO2021079196A9 (en) | Mettl3 modulators | |
| US11518767B2 (en) | MTOR inhibitor compounds | |
| TW202321261A (zh) | 選擇性ｋｒａｓ抑制劑 | |
| JPWO2019122065A5 (ko) | ||
| AU2017350688B2 (en) | Fused azaheterocyclic compounds and their use as AMPA receptor modulators | |
| EP4090661A1 (en) | Quinoxaline derivatives as modulators of the glucocorticoid receptor | |
| GB2504615A (en) | Fused aminodihydrothiazine derivatives |